N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia
Tong J, Yang K, Li W, Wang L, Yin Y, Zhou Y, Huang J, Zhang P, Zhao Y, Chen S, Fan H, Cui Y, Luo X, Tan S, Wang Z, Feng W, Tian B, Li C, Hong L, Tan Y. N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia. Schizophrenia Bulletin 2024, sbae180. PMID: 39406395, DOI: 10.1093/schbul/sbae180.Peer-Reviewed Original ResearchFirst-episode schizophreniaSensory gating deficitsN-methyl-D-aspartate receptorsFirst-episode schizophrenia groupGating deficitsN-methyl-D-aspartateP50 ratioSensory gatingExposure to antipsychotic medicationAb levelsHealthy controlsAntipsychotic medication exposureFirst-episode patientsDiagnosis of schizophreniaImpaired sensory gatingP50 sensory gating deficitN-methyl-D-aspartate receptor antibodiesAntipsychotic medicationFirst-episodeNon-smoking healthy controlsP50 differenceSchizophreniaPartial correlation analysisEnzyme-linked immunosorbent assayDeficits